Table 3 Treatment efficacy of first-line EGFR-TKIs.

From: Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs

 

All (N = 123)*

MINO + (N = 30)

MINO – (N = 93)

P value

Treatment efficacy

 CR

4 (3.3)

3 (10.0)

1 (1.1)

0.048

 PR

88 (71.5)

23 (76.7)

65 (69.9)

 SD

29 (23.6)

4 (13.3)

25 (26.9)

 PD

2 (1.6)

0 (0)

2 (2.2)

ORR

74.8%

86.7%

71.0%

0.096

  1. Data are presented as N (%).
  2. EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, MINO minocycline, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR overall response rate.
  3. *Eleven patients had no target lesion that was assessable based on the Response Evaluation Criteria in Solid Tumors version 1, and four patients did not undergo an imaging assessment.
Back to article page